AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 21st, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 9th day of November, 2018, by and among Keros Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
KEROS THERAPEUTICS, INC. Incentive Stock Option Agreement Granted Under 2017 Stock Incentive PlanIncentive Stock Option Agreement • January 21st, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations
Page ARTICLE 1: BASIC TERMS 1 ARTICLE 2: PREMISES AND APPURTENANT RIGHTS 4 2.01 Lease of Premises; Appurtenant Rights 4 2.02 Roof License 6 ARTICLE 3: LEASE TERM 8 3.01 Lease Term 8 3.02 Hold Over 9 3.03 Right to Extend 9 ARTICLE 4: RENT 11 4.01 Base...Lease • January 21st, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations
THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: [***] MGH Case Nos: [***]Patent License Agreement • January 21st, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations
This License Agreement (“Agreement”) is made as of the 5th day of April, 2016 (“Effective Date”), by and between Keros Therapeutics, Inc., a Delaware corporation, having a principal place of business at 3 Lincoln Terrace, Lexington, MA 02421 (“Company”) and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT BETWEEN KEROS THERAPEUTICS, INC. AND NOVO NORDISK A/SResearch Collaboration and Exclusive License Agreement • January 21st, 2020 • Keros Therapeutics, Inc. • Pharmaceutical preparations • New York
This Research Collaboration and Exclusive License Agreement (“Agreement”) is made and entered into, effective as of December 14, 2017 (“Effective Date”), by and between Keros Therapeutics, Inc., a Delaware corporation, having a principal place of business at Suite 120, Building E, 99 Hayden Avenue, Lexington, MA 02421, USA (“Keros”) and Novo Nordisk A/S, a company organized and existing under the laws of Denmark, having a principal place of business at Novo Allé, DK-2880 Bagsværd, Denmark (“Novo Nordisk”). Keros and Novo Nordisk are each referred to herein individually as a “Party” and collectively as the “Parties”.
